PRM177 What is the Role of Early Health Technology Assessment of Biomarkers in the Pre-Clinical Development Phase? A Reflection on Lessons Learned With Multiple Myeloma  by Gaultney, J.G. et al.
threshold, and 2) the health effects of the new technology with the health effects of
those technologies which must be displaced to accommodate its additional costs.
The performance of each is evaluated through a simulation exercise, which using
shopping at the supermarket as an analogy to the health care system. An initial
basket of goods represents the initial allocation and specifies the budget constraint.
The task is to improve the contents of the basket by examining other things on the
shelves and applying one of the decision rules. Performance is measured by: 1) how
close each can get to the optimal basket (a MP solution), and 2) how quickly each
improves the initial basket. We explore when each decision rule performs at its
best and when one is likely to outperform the other. This includes: indivisibly of
technologies and programmes, size of the budget relative to programme costs, the
efficiency of exiting technologies; the type of information available to decision
makers and whether they are able to learn from examining more products. This
helps to identify where additional information (e.g., a better estimate of the thresh-
old) might be most valuable.
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THE VALUE OF PERSONALIZED MEDICINE: IT IS MORE ABOUT UNVEILING THE
PERFORMANCE OF THE COMPANION DIAGNOSTIC
Ethgen O
University of Liege, Liege, Belgium
Personalized medicine (PM) is notably typified by the development of companion
diagnostic tests to guide optimal treatment selection. PM has thus the potential to
dramatically improve patients’ outcomes and optimise allocation of resources.
However, very few attempts exist that transparently include diagnostic test per-
formance such as Sensitivity (Se) and Specificity (Sp) into cost-effectiveness and
budget impact models. This research proposes an analytical framework to unveil
diagnostic added-value according to different diagnostic performance scenario.
The framework is based on a decision tree and compares two hypothetical treat-
ments N vs. C. N is a new treatment associated with a companion diagnostic test T.
C is the current standard of care not associated with any test. T selects the likely
responding patients based on the presence (T) or absence (T) of a predictive sign
of response to N (a distinctive biomarker for instance). We demonstrate that it is
the prior prevalence of the sign within the target population coupled with the
expected effectiveness differential between N and C in true positive patients and
with the performance of the test (Se and Sp) that are the fundamental determi-
nants of the potential value of a PM strategy. An extension of the model to the case
of 2 competing PM strategies (and thus 2 competing tests) is shown. We conclude
that companion diagnostic test performance is key to achieve the promises of PM.
This analytical framework allows payers, HTA bodies and manufacturers to gauge
the potential value and financial impact of a PM strategy at all stage of its develop-
ment.
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Issues on discounting health effects have spurred debates on appropriate decision
rules. Consensus is that empirically observed rates of time preference be incorpo-
rated in analysis. The latter, however, is known to suffer from cognitive limitations.
The human nervous system perceives how long sensory events last and the latter
impact on perceptual decision making which is the act of choosing from a set of
alternatives on the basis of available sensory evidence; in our case the indifference
balance between present and future consumption. Statistical tools for such pur-
poses are however scarce and normality assumptions often fail to hold. We there-
fore derive a stochastic distribution by maximum entropy principle(MaxEnt). A
MaxEnt distribution is one which best represents the current state of knowledge.
Furthermore, MaxEnt distributions minimize the amount of prior information built
into the distribution. Such distributions are usually sought by maximization of
entropy constrained on what is known. In our case, we assume that the expected
indifference amount at time t compared to an amount, y0, now is given by
E(Y(t))y0/w(t) where w(t) is a general time-inhomogeneous discount weight. With
that constraint and the usual probability constraints, we derive a maximum en-
tropy distribution for such a future amount. That is, we provide a closed-form
distribution of the probability that an individual is indifferent between some quan-
tity Y(t)y at time t and a quantity Y(0)y0 now given E(Y(t))y0/w(t).
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OBJECTIVES: Prostate cancer (PC) is the second most common cancer in men
worldwide and the second leading cause of cancer deaths in men in the United
States. Recently, the prostate specific antigen (PSA) test used to screen and diag-
nosis PC has been questioned due to concerns regarding clinical utility and its
inability to accurately identify men with PC. This research aims to estimate the
Value of Information (VoI) of the PSA screening research and to determine whether
future PSA screening research should be focused on specific populations.
METHODS: This research uses the Minimal Modeling Approach (MMA) in order to
determine the expected value of information for PSA research. The population
expected value of information (pEVI) for racial (African Americans and non-African
Americans) and age (65-75 years, 76-85 years, 85 years) subgroups will be deter-
mined. Investigators will model survival based on published randomized con-
trolled trials of PSA screening and will use data from the Surveillance Epidemiology
and End-Result (SEER)-Medicare dataset for both survival and costs. Investigators
will structure analyses by modeling the net benefit of men who received a prostate
specific antigen screening exam between 2000 and 2007. RESUTS:VoI is recognized
for providing a framework for estimating the expected benefits of clinical research.
Due to the controversy surrounding the PSA screening test, patients and clinicians
are challenged when trying to make informed decisions regarding diagnosis and
treatment of PC.CONCLUSIONS:This research seeks to determine where the great-
est return on research investment would provide a more accurate evidence base for
PSA screening for PC.
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Patient reported outcome (PRO) measures typically undergo a precise and detailed
translation process which involves the input of translators, investigators, project
managers and developers in order to produce the most accurate and fluent trans-
lation possible. In order for the pooling of data from international clinical trials to
be possible, it is important that translations of a PRO measure mean the same to all
respondents, not just in terms of the phrasing, but also in terms of the intensity and
nuance of the phrases used. It is often the case that terms used frequently in PRO
measures will have a direct and literal translation into the target language. How-
ever, problems can occur when terms used in the source text are culturally bound
– i.e., when the direct translation of a term has a different meaning than that of the
source text, in terms of intensity or connotations, or is used in a different way. For
example, the term ‘frustrated’ has a direct translation in most languages; however,
this term has a stronger meaning in some countries and can refer to a mental
health issue. Issues can also arise when there is no equivalent of the source term in
the target language. We will discuss common terms, expressions and nuances that
are frequently used in PRO measures and how their meaning can be different
across varying languages and cultural backgrounds. We will examine how to pre-
empt these issues and how to avoid the mistranslation of culturally bound terms,
by discussing the importance of detailed concept elaboration documents, input
from the instrument developer, and in-depth pilot testing and cognitive debriefing.
By using these methods it is possible to accurately anticipate these potential issues
and explore alternative ways of conveying the intended meaning.
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OBJECTIVES: Judgements based on average cost effectiveness estimates may dis-
guise sources of heterogeneity that should be reflected in decision making. Making
decisions considering between patient heterogeneity has been proved consistent
with an efficient use of limited resources. Although individual level data (IPD) is
often not available to inform decision models, these provide unbiased and more
precise estimates, particularly in the presence of heterogeneity. This paper seeks to
assess the added value of having access to IPD, compared to using aggregate data
(AD) only, in appropriately performing subgroup value of information analysis.
METHODS: This paper develops a framework that informs the understanding of
the implications of considering IPD when assessing the value of additional re-
search in the absence and in the presence of mutually exclusive population
subgroups. RESULTS: The developed framework explores the capabilities of the
available evidence (i.e. IPD and AD) in guiding and in quantifying the value of
further research in the absence and presence of subgroups. Issues around the
optimal number of subgroups and for which population subsets should further
research be undertaken are discussed. These exercises are supported by a moti-
vating example on the cost effectiveness of child accident prevention programmes.
CONCLUSIONS: The use of IPD rather than AD estimates may influence not only
the extent to which an appropriate understanding of existing heterogeneity is
attained, but, more importantly, it may shape approval decisions for particular
population subgroups and judgements of furtherresearch.
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OBJECTIVES: Biomarkers associated with treatment efficacy and safety can be used
to develop pharmacogenomic tests. However, translation of the evidence into clin-
ical practice is difficult due to barriers to development and the difficulty to dem-
onstrate clinical and economic utility. Health technology assessment (HTA) meth-
odology may be used to inform decisions at many points during the product
lifecycle. We assessed the role of HTA in the development phase of pharmacog-
enomic tests in multiple myeloma.METHODS: Early-Stage hta was conducted sep-
arately for two clinical applications of biomarkers: 1) a safety-based companion
diagnostic, and 2) a prognostic test. We reviewed the methods that were useful in
answering the questions about the health benefits and costs of the intervention
and comparators strategies in each scenario were reviewed. RESULTS: An evi-
dence-based approach was applied for both scenarios. Using literature reviews and
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interviews with relevant stakeholders, questions about the target patient popula-
tion, the intervention and standard care could be answered. Some issues arose
such as variation in standard care and the definition of risk categories. Evidence on
the prognostic value of some biomarkers was also found to be inconsistent. Deci-
sion-analytic modelling could be applied to synthesize all available evidence and
estimate the health benefits and costs of the intervention and standard care op-
tions. The influence of the diagnostic accuracy of the test and assumptions about
the patient population and treatment outcomes could be evaluated. Not all ques-
tions regarding the generalizability of the results to other settings could be an-
swered by these techniques. CONCLUSIONS: The role of early HTA for companion
diagnostics is to identify the gaps in evidence on the clinical and economic value of
biomarkers, variation in standard care, and key stakeholders and their preferences.
This information is necessary for forecasting the issues that will be encountered
when positioning a pharmacogenomic test in the market.
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The objective is to automate the migration of complex health economics Excel
models based on Markov chains to modern software platforms, such as Mobile or
Web. In this research project, we have developed a software solution that is capable
of transforming a Microsoft Excel model into a self-contained platform-indepen-
dent programming module. This module fully preserves the original model along
with cell values, formulas and dependencies, and is capable of running the model
independently from the Microsoft Excel environment. The module is used as a
basis for creating web and mobile applications supporting calculations identical to
that in Excel model. These applications will give the user means to manipulate
model inputs and see the results of his actions immediately without having the full
model delivered, thus preserving the confidentiality of proprietary data and algo-
rithms. By using our method, several Excel based Markov cohort models with more
than 1000 cycles were transformed and used as a basis for development of web-
based and iPad applications for health care decision making. These applications
showed performance comparable to Microsoft Excel and complete outcomes cor-
relation with the original model. With the proposed solution, mature Excel models
developed over the years in various institutions can be connected with modern
information technologies in a fast and reliable way. Our method makes automated
model transformation possible without human intrusion into a stable model core.
By eliminating the dependency on Microsoft Excel, we open new ways for integra-
tion of time-proven Excel models with modern software platforms, such as the
Web or Mobile.
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OBJECTIVES: To identify real-world incidence and related costs of hypoglycemia
among T2DM patients initiating insulin glargine (GLA). METHODS: Patient-level
data from 6 published observational retrospective studies using health plan claim
databases were pooled. Included were T2DM patients with continuous health plan
coverage for 6 months before and 1 year after initiation, who were previously on
oral antidiabetic drugs (OADs) or glucagon-like peptide-1 (GLP-1) analogs and ini-
tiated GLA (2007-2009) via disposable pen (GLA-P) or vial/syringe (GLA-V). In each
study, observed differences between the two cohorts were removed by propensity
score matching. Hypoglycemia and associated health care costs were measured
over a 1-year follow-up period. RESULTS: Included were 14,911 GLA-P patients and
8,187 GLA-V patients (age 54.1 years, 53.5% men, mean Charlson Comorbidity Index
0.55, # of OADs 2.45, A1C 9.34% where available). During follow-up, prevalence rates
of any hypoglycemia and inpatient/emergency room (ER)-related hypoglycemia
were low overall, particularly for GLA-P (5.49% vs 7.70% and 1.60% vs 3.26%; both
P0.0001). Incidence rates of any hypoglycemia and inpatient/ER-related hypogly-
cemia were 25.7 and 3.8 events/100 patient years, and lower for GLA-P (any: 20.4 vs
35.5 events/100 patient years; ER-related: 2.6 vs 6.1 events/100 patient years; both
P0.0001). Hypoglycemia-related costs were lower for GLA-P ($225 vs $417;
P0.001). Hypoglycemia-related costs contributed 0.75% of overall health care
costs and 1.5% of diabetes-related health care costs across both cohorts; in the
GLA-P cohort the contribution was 0.55% and 1.07% (both P0.001) of overall and
diabetes-related costs, respectively. A1C reduction from baseline (N1,896) was
larger for GLA-P (1.22% vs 0.86%, P0.0012), and correlated with higher inci-
dence of hypoglycemia (r0.151; P0.0001). CONCLUSIONS: Patients initiating
insulin glargine treatment showed low rates of hypoglycemia, especially when
using a disposable pen device. Hypoglycemia-related costs were low, contributing
a very small proportion to overall and diabetes-related health care costs.
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OBJECTIVES: The use of standard immediate release metformin (MIR) two or three
times daily has been associated with gastrointestinal adverse events (GIAE). Met-
formin XR (MXR) is a once a day extended release formulation that offers a poten-
tial benefit of a decrease in the frequency of GIAE and increased adherence rates in
patients diagnosed with Type 2 Diabetes Mellitus (T2DM). This systematic review
identifies published evidence regarding the efficacy, safety, and adherence of MXR
relative to MIR in the treatment of T2DM. METHODS: We searched relevant bibli-
ographic databases, internet and grey literature, and included all studies with an
analytical or observational design. We assessed the quality of all selected studies
following the Cochrane Collaboration recommendations. When possible, we cal-
culated the mean global effect of MXR vs. MIR for clinical outcomes. RESULTS: The
search identified 81 studies of which 10 met inclusion/exclusion criteria for anal-
ysis. The quality of these 10 studies was generally poor. Efficacy results of 187
patients were included in a meta-analysis that estimated the mean difference with
respect to baseline measurements. Glycosylated hemoglobin (HbA1c) control, fast-
ing plasma glucose and lipid control was similar in both treatments (MD0.01
CI95%-0.38-0.41; MD0.32 CI95%-0.25-0.89; MD0.16 CI95%-0.23-0.54, respec-
tively). The frequency of GIAE was meta-analyzed using data from 1,045 patients,
and the global Relative Risk was estimated (RR 0.97; CI95%0.80-1.19). Patients
treated with MXR experienced a significantly lower incidence of nausea (RR0.82;
CI95%0.46-1.95) and dyspepsia (RR0.64; CI95%0.29-1.43) than patients on MIR.
Adherence was reported in two studies, showing that patients treated with MXR
have a significantly higher adherence to treatment than MIR cohorts.
CONCLUSIONS: Treatment once a day with MXR tablets has comparable efficacy to
a two or three times daily dosage with MIR. MXR offers the benefit of increased
adherence to treatment, and a lower frequency of nausea and dyspepsia compared
to MIR.
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OBJECTIVES: The Initiation of New Injectable Treatment Introduced after Anti-
diabetic Therapy with Oral-only Regimens (INITIATOR) study aims to investigate
real-world outcomes among T2DM patients failing oral antidiabetic drugs (OADs)
and initiating injectable therapy with insulin glargine (GLA-P) or the glucagon-like
peptide 1 analog liraglutide (LIRA). This analysis reports treatment pattern data
from the pilot retrospective study phase of INITIATOR. METHODS: Two indepen-
dent administrative claims databases from OptumInsight™ (OI) and HealthCore®
(HC) were assessed retrospectively. Data were included from adult T2DM patients
previously on OADs only, initiating GLA-P or LIRA injectable therapy (January–July
2010) with continuous health care coverage during the 6 months before (baseline),
and 9 (OI) or 12 months (HC) after initiation (follow-up). Baseline characteristics,
treatment patterns, and outcomes among GLA-P and LIRA cohorts were assessed
descriptively. RESULTS: 2,684 patients were included (OI: GLA-P n610, LIRA
n365; HC: GLA-P n1,188, LIRA n521). Compared to LIRA patients, GLA-P initia-
tors were older (56 years vs 53 years; P0.001), less obese (9.2%-12% vs 18%-19%; OI:
P0.01, HC: P0.001), had higher comorbidity (CCI 1.1-1.2 vs 0.6-0.7; P0.001) and
higher A1C (9.1%-9.7% vs 7.7%-7.9%; P0.001), and were much less likely to have
baseline A1C 7.0% (9%-11% vs 30%-34%; P0.001).During follow-up, the 9-month
(OI) treatment persistence rate was 63.1% for GLA-P and 52.1% for LIRA; the 12-
month (HC) rate was 60.2% for GLA-P and 50.9% for LIRA. Total annualized all-cause
health care costs for GLA-P vs LIRA, respectively, were $16,560 vs $14,984 (OI), and
$16,466 vs $14,579 (HC). Study drugs contributed 7% (GLA-P) and 17%-19% (LIRA) to
the total costs. CONCLUSIONS: GLA-P and LIRA are prescribed to very different
T2DM patients in a real-world setting, with about 1/3 of LIRA initiators character-
ized by baseline A1C 7.0%. These differences in patient characteristics need to be
taken into account when conducting related comparative effectiveness research.
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OBJECTIVES: For the management of T2DM using combination therapy with PIO
and DPP4i, there is no consensus on whether to initiate both drugs simultaneously
or start with PIO followed by sequential addition of DPP4i. We aimed to assess
impact of initial vs. sequential combination therapy with PIO and DPP4i on HbA1C
reduction. METHODS: A chart review was conducted among people with T2DM to
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